January 2, 2020 — In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease. EACTS leadership said the reason was because the results of the EXCEL randomized clinical trial were misleading because of the definitions used for myocardial infarction (MI).[1] 

December 30, 2019 — Merit Medical Systems Inc., a leading manufacturer of proprietary devices used primarily in cardiology, radiology, oncology and endoscopy, announces the commercial launch of the PreludeSYNC EVO radial compression device in European, Middle Eastern and African markets.

The product has FDA clearance in the U.S. and CE Mark approval in the EU for use in diagnostic cardiac catheterisation procedures and percutaneous coronary interventions.

December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained and significant reductions in triglyceride levels using low dosages. The findings were recently reported in a late-breaking presentation at the American Heart Association Scientific Sessions 2019 by Dr.

December 30, 2019 — Eko, a digital health company with an AI-powered cardiac screening platform, announced the second generation of its CORE product line. An evolution from Eko's first-generation CORE, the new CORE features powerful amplification and active noise cancellation that enables doctors and nurses to hear heart and lung sounds with greater clarity and screen patients for heart disease, the number one cause of death in the U.S., more effectively.